These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15464315)

  • 1. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial.
    Grube E; Lansky A; Hauptmann KE; Di Mario C; Di Sciascio G; Colombo A; Silber S; Stumpf J; Reifart N; Fajadet J; Marzocchi A; Schofer J; Dumas P; Hoffmann R; Guagliumi G; Pitney M; Russell ME;
    J Am Coll Cardiol; 2004 Oct; 44(7):1368-72. PubMed ID: 15464315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent.
    Grube E; Schofer J; Hauptmann KE; Nickenig G; Curzen N; Allocco DJ; Dawkins KD
    JACC Cardiovasc Interv; 2010 Apr; 3(4):431-8. PubMed ID: 20398872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial.
    Serruys PW; Ormiston JA; Sianos G; Sousa JE; Grube E; den Heijer P; de Feyter P; Buszman P; Schömig A; Marco J; Polonski L; Thuesen L; Zeiher AM; Bett JH; Suttorp MJ; Glogar HD; Pitney M; Wilkins GT; Whitbourn R; Veldhof S; Miquel K; Johnson R; Coleman L; Virmani R;
    J Am Coll Cardiol; 2004 Oct; 44(7):1363-7. PubMed ID: 15464314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.
    Haude M; Lee SW; Worthley SG; Silber S; Verheye S; Erbs S; Rosli MA; Botelho R; Meredith I; Sim KH; Stella PR; Tan HC; Whitbourn R; Thambar S; Abizaid A; Koh TH; Den Heijer P; Parise H; Cristea E; Maehara A; Mehran R
    JACC Cardiovasc Interv; 2013 Apr; 6(4):334-43. PubMed ID: 23523459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE).
    Kataoka T; Grube E; Honda Y; Morino Y; Hur SH; Bonneau HN; Colombo A; Di Mario C; Guagliumi G; Hauptmann KE; Pitney MR; Lansky AJ; Stertzer SH; Yock PG; Fitzgerald PJ
    Circulation; 2002 Oct; 106(14):1788-93. PubMed ID: 12356631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome.
    Liistro F; Stankovic G; Di Mario C; Takagi T; Chieffo A; Moshiri S; Montorfano M; Carlino M; Briguori C; Pagnotta P; Albiero R; Corvaja N; Colombo A
    Circulation; 2002 Apr; 105(16):1883-6. PubMed ID: 11997271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.
    Mehilli J; Byrne RA; Tiroch K; Pinieck S; Schulz S; Kufner S; Massberg S; Laugwitz KL; Schömig A; Kastrati A;
    J Am Coll Cardiol; 2010 Jun; 55(24):2710-6. PubMed ID: 20226618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
    Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
    Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent.
    Meredith IT; Verheye S; Dubois CL; Dens J; Fajadet J; Carrié D; Walsh S; Oldroyd KG; Varenne O; El-Jack S; Moreno R; Joshi AA; Allocco DJ; Dawkins KD
    J Am Coll Cardiol; 2012 Apr; 59(15):1362-70. PubMed ID: 22341736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
    Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial.
    Waksman R; Piegari GN; Kabour A; Cannon L; Wang J; Adams G; Solankhi N; Smeglin A; Kereiakes DJ; Leiboff R; Spad MA; Torguson R; Chandra N; Bastian R; DeGroot J; Kayo MW; Stoll HP; Garcia-Garcia HM
    Cardiovasc Revasc Med; 2017; 18(7):475-481. PubMed ID: 28923692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
    Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME;
    Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
    Krucoff MW; Kereiakes DJ; Petersen JL; Mehran R; Hasselblad V; Lansky AJ; Fitzgerald PJ; Garg J; Turco MA; Simonton CA; Verheye S; Dubois CL; Gammon R; Batchelor WB; O'Shaughnessy CD; Hermiller JB; Schofer J; Buchbinder M; Wijns W;
    J Am Coll Cardiol; 2008 Apr; 51(16):1543-52. PubMed ID: 18420096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
    Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
    JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.